ToltrazurilCAS# 69004-03-1 |
- Biapenem
Catalog No.:BCC1071
CAS No.:120410-24-4
- (S)-Tedizolid
Catalog No.:BCC1294
CAS No.:1431699-67-0
- Aprepitant
Catalog No.:BCC1101
CAS No.:170729-80-3
- Tulathromycin A
Catalog No.:BCC2019
CAS No.:217500-96-4
- Doripenem Hydrate
Catalog No.:BCC1160
CAS No.:364622-82-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 69004-03-1 | SDF | Download SDF |
| PubChem ID | 68591 | Appearance | Powder |
| Formula | C18H14F3N3O4S | M.Wt | 425.38 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (235.08 mM) *"≥" means soluble, but saturation unknown. | ||
| Chemical Name | 1-methyl-3-[3-methyl-4-[4-(trifluoromethylsulfanyl)phenoxy]phenyl]-1,3,5-triazinane-2,4,6-trione | ||
| SMILES | CC1=C(C=CC(=C1)N2C(=O)NC(=O)N(C2=O)C)OC3=CC=C(C=C3)SC(F)(F)F | ||
| Standard InChIKey | OCINXEZVIIVXFU-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H14F3N3O4S/c1-10-9-11(24-16(26)22-15(25)23(2)17(24)27)3-8-14(10)28-12-4-6-13(7-5-12)29-18(19,20)21/h3-9H,1-2H3,(H,22,25,26) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Toltrazuril Dilution Calculator
Toltrazuril Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.3508 mL | 11.7542 mL | 23.5084 mL | 47.0168 mL | 58.771 mL |
| 5 mM | 0.4702 mL | 2.3508 mL | 4.7017 mL | 9.4034 mL | 11.7542 mL |
| 10 mM | 0.2351 mL | 1.1754 mL | 2.3508 mL | 4.7017 mL | 5.8771 mL |
| 50 mM | 0.047 mL | 0.2351 mL | 0.4702 mL | 0.9403 mL | 1.1754 mL |
| 100 mM | 0.0235 mL | 0.1175 mL | 0.2351 mL | 0.4702 mL | 0.5877 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Toltrazuril is an antiprotozoal agent that acts upon Coccidia parasites.
- Norchelerythrine
Catalog No.:BCN3643
CAS No.:6900-99-8
- Lycodoline
Catalog No.:BCN2506
CAS No.:6900-92-1
- Hypaconitine
Catalog No.:BCN5988
CAS No.:6900-87-4
- 2,6-Dihydroxypurine
Catalog No.:BCN8476
CAS No.:69-89-6
- Maltose
Catalog No.:BCC8338
CAS No.:69-79-4
- Cytarabine hydrochloride
Catalog No.:BCC4116
CAS No.:69-74-9
- Salicylic acid
Catalog No.:BCC4109
CAS No.:69-72-7
- D-Mannitol
Catalog No.:BCN2205
CAS No.:69-65-8
- Penicillin G Sodium
Catalog No.:BCC4638
CAS No.:69-57-8
- Ampicillin
Catalog No.:BCC1199
CAS No.:69-52-3
- Chlorpromazine HCl
Catalog No.:BCC4460
CAS No.:69-09-0
- Quinacrine 2HCl
Catalog No.:BCC4709
CAS No.:69-05-6
- Toltrazuril sulfone
Catalog No.:BCC2008
CAS No.:69004-04-2
- Tiotidine
Catalog No.:BCC5676
CAS No.:69014-14-8
- Genipin
Catalog No.:BCN5932
CAS No.:6902-77-8
- Germacrone
Catalog No.:BCN4981
CAS No.:6902-91-6
- ZM 306416
Catalog No.:BCC3964
CAS No.:690206-97-4
- Balapiravir
Catalog No.:BCC1396
CAS No.:690270-29-2
- Grifolin
Catalog No.:BCN7553
CAS No.:6903-07-7
- Hydroxytyrosol acetate
Catalog No.:BCN2963
CAS No.:69039-02-7
- Nedocromil
Catalog No.:BCC5283
CAS No.:69049-73-6
- Delphinidin-3-O-glucoside chloride
Catalog No.:BCN3020
CAS No.:6906-38-3
- Peonidin-3-O-glucoside chloride
Catalog No.:BCN3028
CAS No.:6906-39-4
- 4'-Prenyloxyresveratrol
Catalog No.:BCN2937
CAS No.:69065-16-3
Efficacy of treatments with toltrazuril 7.5% and lasalocid sodium in sheep naturally infected with Eimeria spp.[Pubmed:27580396]
Rev Bras Parasitol Vet. 2016 Jul-Sep;25(3):293-8.
The objective of this study was to evaluate the efficacy of an experimental formulation of Toltrazuril 7.5% + Trimix on a naturally acquired infection of Eimeria spp. in suckling lambs kept on pasture and, in another trial, evaluate the comparative efficacy between lasalocid and Toltrazuril 7.5% + Trimix in newly weaned sheep under feedlot conditions that had been naturally infected with Eimeria spp. In the first experiment, 30 suckling lambs were divided into two groups: A - treated with Toltrazuril 7.5% + Trimix and B- control. In experiment 2, 30 weaned sheep were divided into three groups: I - treated with Toltrazuril 7.5% + Trimix, II - treated with lasalocid and III - control. Treatment group A showed an efficacy of 90, 99.4 and 87.3% on days 5, 10 and 20, respectively. Treatment group I had an efficacy of 98.2, 92.6 and 94.5%, while group II had an efficacy of 72.7, 81.6 and 95.9% on days 7, 21 and 42, respectively. Eight Eimeria species were identified; E. ovinoidalis was the most common. Treatment with the Toltrazuril 7.5% +Trimix formulation was effective against Eimeria spp. in suckling lambs in field conditions and lambs weaned in under feedlot conditions.
Metaphylactic treatment strategies with toltrazuril and diclazuril and growth performance of buffalo calves exposed to a natural eimeria infection.[Pubmed:26215929]
Vet Parasitol. 2015 Sep 15;212(3-4):408-10.
Five controlled field trials were conducted in southern Italy to evaluate the effect of metaphylactic treatment strategies of Toltrazuril and diclazuril for the control of coccidiosis in water buffaloes naturally infected by Eimeria spp. The 5 farms were divided into two types (A and B) according to their management system (individual or collective breeding of buffalo calves). In the farms of type A (no. 3), the buffalo calves were bred in individual boxes from the birth to the 7th/8th week of age and then transferred to concrete based pens; in the farms of type B (no. 2) the calves were bred in groups on concrete based pens from the birth. On each farm, 36 calves aged 5 weeks were divided at random into three similar groups of 12. One group was treated with Toltrazuril (TOL), the second group was treated with diclazuril (DIC) and the third group was remained as untreated control group (CONT). On each farm the calves were weighed weekly and clinically examined. In the 5 buffalo farms the average oocyst excretion decreased significantly in both the treated groups (TOL and DIC), however the TOL groups had significantly low counts than the DIC groups. The body-weight gains recorded fortnightly were significantly higher in the TOL groups (range=5.4-8.1 kg) compared to the DIC (range=1.7-3.1 kg).
Field Evaluation of the Effectiveness of an Oral Toltrazuril and Iron Combination (Baycox(R) Iron) in Maintaining Weaning Weight by Preventing Coccidiosis and Anaemia in Neonatal Piglets.[Pubmed:26152420]
Parasitol Res. 2015 Aug;114 Suppl 1:S193-200.
Effectiveness of an oral combination of Toltrazuril and iron dextran (Baycox((R)) Iron) to maintain weaning weight by preventing coccidiosis caused by Isospora suis and iron-deficiency anaemia in neonatal piglets was investigated on three commercial pig farms with a history of coccidiosis: two in Mexico and one in Brazil. On day (SD) 2 of life, piglets were randomised within litter by bodyweight to treatment or control group. On SD 3 piglets allocated to the control group (CG) each received 1 mL Baycox((R)), containing 50 mg/mL Toltrazuril orally and commercially available iron (200 mg/piglet) by intramuscular injection. Piglets allocated to the treatment group (TG) each received 1 mL Toltrazuril and iron combination orally (Baycox((R)) Iron) containing 50 mg/mL Toltrazuril and 228 mg iron as iron dextran. All piglets had access to creep feed. 6493 piglets completed the study. Bodyweight at weaning on SD 21 of piglets treated with the oral Toltrazuril and iron combination was confirmed to be non-inferior to the control treatment with <1 % difference between group mean body weights. Faecal samples from at least 10 % of litters on SD 14 demonstrated control of coccidiosis. Haemoglobin levels on SD 21 were lower in the oral Toltrazuril and iron combination treated piglets compared to control levels but above minimum haemoglobin levels to maintain health. There was no difference in mortality between the two groups. This large scale field evaluation clearly demonstrated the effectiveness of a combination of oral Toltrazuril and iron (Baycox((R)) Iron) in maintaining body weight at weaning compared to conventional treatment. The combination was effective in preventing coccidiosis and anaemia and thus provides a valuable alternative that reduces stressful events in neonatal piglets. There were no product related adverse events.
Significance of Timing on Effect of Metaphylactic Toltrazuril Treatment against Eimeriosis in Calves.[Pubmed:26152421]
Parasitol Res. 2015 Aug;114 Suppl 1:S201-12.
In this multicentric, randomised, blinded and placebo-controlled field study, the effect of treatment with Toltrazuril (Baycox((R)) Bovis, Bayer) on oocyst excretion, diarrhoea score and weight gain was studied in Danish dairy herds with confirmed history of eimeriosis (coccidiosis) and prevalence of Eimeria bovis and Eimeria zuernii. Three commercial herds and a total of 71 calves, aged 48 - 135 days, were included. Treatment with a single oral dose of Toltrazuril (15 mg/kg) was given after relocation to common pens and one week before expected outbreak of eimeriosis. The effect of treatment was followed by weekly faecal sampling and weighing initially and at the end of a study period of 8 weeks. In Herd 2 and 3 Toltrazuril treated calves gained on average 7.95 kg more than placebo treated calves (p = 0.007), and both oocyst excretion and prevalence of Eimeria spp. were significantly reduced the first weeks post treatment. In Herd 1, by contrast, the farmer made some unforeseen changes in the management which entailed relocation to large deep-litter pens 3 - 6 weeks post treatment. In addition, many calves were not treated metaphylactically while few calves excreted oocysts when the trial was initiated. Thus, no significant difference in weight gain was found between Toltrazuril and placebo treated calves (p = 0.523), and the oocyst excretion of Toltrazuril treated calves was significantly higher during week 7 and 8. Significant differences in faecal scores were observed between the herds (p<0.002) but not between treatment groups in any of the herds. In conclusion, timing of treatment is crucial for optimal effect of metaphylactic Toltrazuril treatment on weight gain and oocyst excretion.
